Cell line · CVCL_0161
Papers43
1 to 20 of 43
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Systematic Targeting of Protein Complexes with Molecular COUPLrs. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Autoinhibition of the mechanosensitive lipid scramblase TMEM63B by its C-terminal tail. | J Biol Chem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Function-driven design of a surrogate interleukin-2 receptor ligand. | FEBS Lett | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Chronic ER Stress Triggers Cell-Surface Chaperones as the Therapeutic Targets of CAR Cells in Acute Myeloid Leukemia. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ARAP1 fine-tunes F-actin polymerization level in lymphocytes through RhoA inhibition. | Front Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Association of fibronectin 1 deregulation with tyrosine kinase inhibitor resistance in chronic myeloid leukemia. | Front Cell Dev Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| C3G deregulation uncovers a dual role in B-cell lymphoma: tumor suppression and enhanced metastasis via Rap1 and Rac2 signaling. | Cell Commun Signal | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical assessment of two FcγRI-specific antibodies that competitively inhibit immune complex-FcγRI binding to suppress autoimmune responses. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The influence of ROS1 fusion partners and resistance mechanisms in ROS1-TKI-treated non-small cell lung cancer patients. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A long-lasting prolactin stimulates galactopoiesis in mice. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Protein kinase B inhibitors enhance the sensitivity of translocated promoter region-fibroblast growth factor receptor 1 cells to fibroblast growth factor receptor 1 inhibitor-induced apoptosis. | J Int Med Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Downregulation of S6 Kinase and Hedgehog-Gli1 by Inhibition of Fatty Acid Synthase in AML with FLT3-ITD Mutation. | Int J Mol Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Discovery and Characterization of a First-in-Class LIV1-TLR7/8 Immunomodulatory Conjugate with Robust Myeloid Activation and Antitumor Activity. | J Med Chem | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0161/papers